中国抗体-B午前大涨32% SM17临床数据表现优异

iDoNews
29 Apr

4月29日,中国抗体-B(03681)午前股价大涨31.85%,报1.78港元。公司宣布SM17在中国治疗中重度特异性皮炎的1B期临床试验中取得积极结果。数据显示,超过90%的患者达到NRS-4应答,70%达到EASI75应答,且未发生严重不良事件。SM17是一款全球首创的人源化单克隆抗体,其作用机制创新,可解决多种自身免疫性疾病需求。据预测,2034年全球特应性皮炎药物市场规模将达314.4...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10